{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:43:47Z","timestamp":1771209827564,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Efforts to improve the outcome of prostate cancer (PC) patients after radical prostatectomy (RP) include adjuvant or salvage radiation therapy (SRT), but still up to 50% of patients develop a disease progression after radiotherapy (RT). Regional hyperthermia (HT) is well-known to improve tumor sensitivity to RT in several entities. Here we report on a planned interim analysis of tolerability and feasibility after recruitment of the first 50 patients of a trial combining SRT and HT. We conducted a prospective multicenter non-randomized Phase-II-Trial (HTProstate-NCT04159051) investigating the implementation of combined moderate-dose escalated SRT (70 Gy in 35 fractions) and locoregional deep HT (7\u201310 HT sessions). The primary endpoints were the rate of acute genitourinary (GU), gastrointestinal (GI), and HT-related toxicities, completed HT sessions (\u22657), and SRT applications per protocol (\u226595% of patients). The two-step design included a planned interim analysis for acute GU-, GI- and HT-specific toxicities to ensure patients\u2019 safety. Between November 2016 and December 2019, 52 patients entered into the trial. After 50 patients completed therapy and three months of follow-up, we performed the planned interim analysis. 10% of patients developed acute grade 2 GU and 4% grade 2 GI toxicities. No grade \u22653 GU or GI toxicities occurred. HT-specific symptoms grade 2 and 3 were observed in 4% and 2% of all patients. Thus, the pre-specified criteria for safety and continuation of recruitment were met. Moreover, \u22657 HT treatments were applicable, indicating the combination of SRT + HT to be feasible. Evaluation of early QoL showed no significant changes. With its observed low rate of GU and GI toxicities, moderate and manageable rates of HT-specific symptoms, and good feasibility, the combined SRT + HT seems to be a promising treatment approach for biochemical recurrence after RP in PC patients.<\/jats:p>","DOI":"10.3390\/cancers13051133","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T20:20:43Z","timestamp":1615148443000},"page":"1133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Salvage-Radiation Therapy and Regional Hyperthermia for Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Results of the Planned Interim Analysis)"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1940-2571","authenticated-orcid":false,"given":"Marcus","family":"Beck","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirus","family":"Ghadjar","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-4290","authenticated-orcid":false,"given":"Felix","family":"Mehrhof","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Eberhard-Karls-University T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-528X","authenticated-orcid":false,"given":"Frank","family":"Paulsen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Eberhard-Karls-University T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wegener","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Eberhard-Karls-University T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susen","family":"Burock","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Comprehensive Cancer Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-5629","authenticated-orcid":false,"given":"David","family":"Kaul","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Stromberger","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Nadobny","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-6158","authenticated-orcid":false,"given":"Oliver J.","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Budach","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wust","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt-Christian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Eberhard-Karls-University T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Zschaeck","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Department of Radiation Oncology, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncpuro0145","article-title":"Rising prostate-specific antigen after primary prostate cancer therapy","volume":"2","author":"Ward","year":"2005","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1200\/JCO.2006.09.6495","article-title":"Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794","volume":"25","author":"Swanson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0022-5347(05)67817-2","article-title":"Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer","volume":"163","author":"Pisansky","year":"2000","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1200\/JCO.2015.63.3529","article-title":"Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09\/10","volume":"33","author":"Ghadjar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: Results of a randomized Phase III Trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijrobp.2007.09.047","article-title":"Improved outcomes with higher doses for salvage radiotherapy after prostatectomy","volume":"71","author":"King","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2007.10.008","article-title":"Radiotherapy after prostatectomy: Is the evidence for dose escalation out there?","volume":"71","author":"King","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ejca.2011.08.013","article-title":"Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling","volume":"48","author":"Ohri","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2016.10.026","article-title":"The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis","volume":"121","author":"King","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): A 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2017.06.027","article-title":"A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer","volume":"73","author":"Spratt","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijrobp.2017.02.019","article-title":"External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: Results of a multicenter, prospective study of quality of life","volume":"98","author":"Gay","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(02)00818-5","article-title":"Hyperthermia in combined treatment of cancer","volume":"3","author":"Wust","year":"2002","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fonc.2017.00132","article-title":"Integrating hyperthermia into modern radiation oncology: What evidence is necessary?","volume":"7","author":"Peeken","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","article-title":"Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 randomized clinical trial","volume":"4","author":"Issels","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0360-3016(97)00109-0","article-title":"Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate","volume":"37","author":"Anscher","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/0265673031000063855","article-title":"A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia","volume":"19","author":"Hofman","year":"2003","journal-title":"Int. J. Hyperth."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00066-005-1296-8","article-title":"Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0","volume":"181","author":"Tilly","year":"2005","journal-title":"Strahlenther Onkol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/02656730701553260","article-title":"Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study","volume":"23","author":"Maluta","year":"2007","journal-title":"Int. J. Hyperth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1464-410X.2004.04551.x","article-title":"Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: Preliminary results","volume":"93","author":"Raaymakers","year":"2004","journal-title":"BJU Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ijrobp.2013.11.212","article-title":"Quantifying the combined effect of radiation therapy and hyperthermia in terms of equivalent dose distributions","volume":"88","author":"Kok","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13014-015-0442-4","article-title":"Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial","volume":"10","author":"Muller","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00066-011-1145-x","article-title":"Quality assurance for clinical studies in regional deep hyperthermia","volume":"187","author":"Bruggmoser","year":"2011","journal-title":"Strahlenther Onkol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/02656739809018219","article-title":"ESHO quality assurance guidelines for regional hyperthermia","volume":"14","author":"Lagendijk","year":"1998","journal-title":"Int. J. Hyperth."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0360-3016(02)04144-5","article-title":"Clinical use of the hyperthermia treatment planning system HyperPlan to predict effectiveness and toxicity","volume":"55","author":"Sreenivasa","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/02656730701827557","article-title":"RF-power and temperature data analysis of 444 patients with primary cervical cancer: Deep hyperthermia using the Sigma-60 applicator is reproducible","volume":"23","author":"Fatehi","year":"2007","journal-title":"Int. J. Hyperth."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/02656730150502323","article-title":"Temperature data and specific absorption rates in pelvic tumours: Predictive factors and correlations","volume":"17","author":"Tilly","year":"2001","journal-title":"Int. J. Hyperth."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00066-018-1269-3","article-title":"Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy","volume":"194","author":"Ghadjar","year":"2018","journal-title":"Strahlenther Onkol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Yokomizo, A., Wakabayashi, M., Satoh, T., Hashine, K., Inoue, T., Fujimoto, K., Egawa, S., Habuchi, T., Kawashima, K., and Ishizuka, O. (2019). Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: A randomised, multicentre, open-label, Phase 3 Trial (JCOG0401)(dagger). Eur. Urol.","DOI":"10.1016\/j.eururo.2019.11.023"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2007.07.017","article-title":"Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC radiation oncology group","volume":"84","author":"Poortmans","year":"2007","journal-title":"Radiother Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"Bottomley","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.11386","article-title":"The memorial anxiety scale for prostate cancer: Validation of a new scale to measure anxiety in men with with prostate cancer","volume":"97","author":"Roth","year":"2003","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:34:09Z","timestamp":1760160849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["cancers13051133"],"URL":"https:\/\/doi.org\/10.3390\/cancers13051133","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]}}}